Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase

被引:65
|
作者
Hamstra, DA
Rice, DJ
Fahmy, S
Ross, BD
Rehemtulla, A
机构
[1] Univ Michigan, Sch Med, Dept Radiat Oncol, Med Ctr, Ann Arbor, MI 48105 USA
[2] Univ Michigan, Med Ctr, Dept Pharmacol, Ann Arbor, MI 48105 USA
[3] Univ Michigan, Med Ctr, Dept Radiol, Ann Arbor, MI 48105 USA
[4] Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48105 USA
关键词
D O I
10.1089/10430349950017356
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The use of cytosine deaminase (CD) in conjunction with 5-fluorocytosine (5-FC) has been studied for cancer gene therapy as a means of achieving tumor-specific generation of the toxic metabolite 5-fluorouracil (5-FU), Since 5-FC is frequently used as an antifungal agent, and because it has little or no efficacy as an antibacterial agent, we hypothesized that yeast CD (YCD) might be more efficient at utilizing 5-FC as a substrate and hence be a better choice for a CD/5-FC gene therapy strategy than the typically utilized bacterial CD (BCD), To that end Saccharomyces cerevisiae CD was cloned from yeast genomic DNA and expressed in vitro. Functional analysis of BCD and YCD expressed in COS-1 cells indicated that BCD and YCD both utilized cytosine with equal efficacy; however, 5-FC was an extremely poor substrate for BCD, with an apparent catalytic efficiency 280-fold lower than that observed for YCD, Retroviral infection of tumor cell lines in vitro indicated that the IC50 of 5-FC was 30-fold lower in PCD-infected cultures as compared with cultures infected with BCD retrovirus, In addition, when SCCVII murine squamous cell carcinoma cells were infected in vitro at low rates of infection (less than or equal to 10%) there was no significant cytotoxicity toward BCD-expressing cells while there was potent cytotoxicity to both YCD-expressing cells and "bystander cells" even at this low level of expression. Finally, stable BCD- or YCD-expressing SCCVII clones were developed and used in an orthotopic immune-competent model of head and neck cancer. Subsequent treatment with 5-FC followed by monitoring of tumor growth by noninvasive magnetic resonance imaging (MRI) and survival of animals indicated a growth delay during the course of 5-FC treatment for BCD-expressing tumors, which quickly regrew at the end of treatment. In contrast, YCD-expressing tumors exhibited not only a growth delay, which was of longer duration, but also in some cases frank tumor regression and complete cures occurred.
引用
收藏
页码:1993 / 2003
页数:11
相关论文
共 50 条
  • [21] TREATMENT OF A XENOGRAFT MODEL OF GLIOBLASTOMA MULTIFORME WITH YEAST CYTOSINE DEAMINASE PRODRUG THERAPY
    Serwer, Laura
    Van Der Aa, Marieke
    Cao, Limin
    Platt, Virginia
    Jerger, Katherine
    Lagpacan, Leanna
    Szoka, Francis
    NEURO-ONCOLOGY, 2008, 10 (05) : 791 - 791
  • [22] Enzyme prodrug therapy of cancer
    Blakey, D
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1997, 7 (09) : 965 - 977
  • [23] Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy
    Wang, DF
    Ruan, HJ
    Hu, L
    Lamborn, KR
    Kong, EL
    Rehemtulla, A
    Deen, DF
    CANCER GENE THERAPY, 2005, 12 (03) : 276 - 283
  • [24] Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy
    Dongfang Wang
    Hangjun Ruan
    Lily Hu
    Kathleen R Lamborn
    Eileen L Kong
    Alnawaz Rehemtulla
    Dennis F Deen
    Cancer Gene Therapy, 2005, 12 : 276 - 283
  • [25] Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy
    Wang, DF
    Ruan, HJ
    Hu, L
    Lamborn, KR
    Rehemtulla, A
    Deen, DF
    CANCER GENE THERAPY, 2004, 11 (12) : 857 - 857
  • [26] Combined radiation and enzyme/prodrug treatment for head and neck cancer in an orthotopic animal model
    Hamstra, DA
    Rice, DJ
    Pu, A
    Oyedijo, D
    Ross, BD
    Rehemtulla, A
    RADIATION RESEARCH, 1999, 152 (05) : 499 - 507
  • [27] Synthesis and characterization of a novel chitosan based E. coli cytosine deaminase nanocomposite for potential application in prodrug enzyme therapy
    Yata, Vinod Kumar
    Ghosh, Siddhartha Sankar
    BIOTECHNOLOGY LETTERS, 2011, 33 (01) : 153 - 157
  • [28] Synthesis and characterization of a novel chitosan based E. coli cytosine deaminase nanocomposite for potential application in prodrug enzyme therapy
    Vinod Kumar Yata
    Siddhartha Sankar Ghosh
    Biotechnology Letters, 2011, 33 : 153 - 157
  • [29] Gene-Directed Enzyme/Prodrug Therapy Using Cytosine Deaminase and Interferon-beta in Engineered Stem Cells Plays a Role in Migration to Endometrian Cancer Cells and Their Growth Inhibition
    Kang, Nam-Hee
    Choi, Kyung-Chul
    BIOLOGY OF REPRODUCTION, 2011, 85
  • [30] Effect of alginate microencapsulation on the catalytic efficiency and in vitro enzyme-prodrug therapeutic efficacy of cytosine deaminase and of recombinant E. coli expressing cytosine deaminase
    Funaro, Michael G.
    Nemani, Krishnamurthy V.
    Chen, Zhihang
    Bhujwalla, Zaver M.
    Griswold, Karl E.
    Gimi, Barjor
    JOURNAL OF MICROENCAPSULATION, 2016, 33 (01) : 64 - 70